Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $532.24, for a total transaction of $5,056,280.00. Following the sale, the chief executive officer owned 324,443 shares in the company, valued at $172,681,542.32. This trade represents a 2.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $524.70 on Thursday. The stock has a market capitalization of $22.27 billion, a price-to-earnings ratio of 19.37, a PEG ratio of 1.75 and a beta of 0.58. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The stock’s 50 day moving average price is $545.45 and its two-hundred day moving average price is $532.24.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same quarter last year, the business earned $6.63 earnings per share. United Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. On average, equities research analysts forecast that United Therapeutics Corporation will post 26.65 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

Several large investors have recently modified their holdings of UTHR. Leuthold Group LLC increased its stake in shares of United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after acquiring an additional 3,126 shares in the last quarter. UBS Group AG lifted its holdings in shares of United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after purchasing an additional 70,445 shares in the last quarter. Perpetual Ltd purchased a new stake in United Therapeutics in the 4th quarter valued at $1,059,000. Brookstone Capital Management lifted its position in shares of United Therapeutics by 25.4% during the fourth quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock valued at $3,227,000 after purchasing an additional 1,342 shares in the last quarter. Finally, LBP AM SA bought a new position in shares of United Therapeutics during the 4th quarter worth approximately $9,745,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

UTHR has been the topic of several analyst reports. Bank of America dropped their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. Weiss Ratings reiterated a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. JPMorgan Chase & Co. raised their price objective on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Finally, Raymond James Financial assumed coverage on shares of United Therapeutics in a research report on Friday, April 10th. They issued an “outperform” rating and a $700.00 target price for the company. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $648.33.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Promising ralinepag trial results: The Lancet published full results from United Therapeutics’ ADVANCE OUTCOMES study. Investigational pulmonary arterial hypertension treatment ralinepag reduced the risk of clinical worsening by 55% versus placebo, improving the company’s potential pipeline outlook. Ralinepag is not yet approved by the FDA, so regulatory and commercialization risks remain. United Therapeutics Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
• Positive Sentiment: Analyst support remains strong: Eleven analysts rate UTHR a Buy and two rate it a Hold, producing a consensus “Moderate Buy” rating. The average price target is $648.33, with JPMorgan recently raising its target to $687 and HC Wainwright increasing its target to $660. United Therapeutics Given Average Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Institutional ownership is high: Hedge funds and other institutional investors own approximately 94.1% of UTHR’s shares. Several institutions increased their positions during the second quarter, signaling continued professional-investor interest, although this does not guarantee further gains. United Therapeutics Insider Trading Report
• Negative Sentiment: CEO stock sale may pressure sentiment: CEO Martine Rothblatt sold 9,500 shares for roughly $5.04 million, reducing her direct stake by 2.84%. She still owns a substantial position, so the transaction may reflect liquidity or diversification rather than a negative view of the business, but insider selling can weigh on investor confidence. Insider Selling United Therapeutics CEO Sells Stock
• Negative Sentiment: Recent operating results were below expectations: United Therapeutics previously reported quarterly earnings and revenue below consensus, with revenue declining 1.6% year over year. That performance remains a concern despite the company’s strong profitability and promising pipeline.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.